A new research paper was published in Volume 18 of Aging-US on March 26, 2026, titled "Effects of intravenous furosemide plus ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
SQ Innovation's Lasix(R) ONYU Now Available for Order Through Major U.S. Pharmaceutical Distributors
The MarketWatch News Department was not involved in the creation of this content. Addressing a Leading Cause of Hospitalization in Older Adults with Heart Failure BURLINGTON, Mass., Feb. 9, 2026 ...
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and ...
Introduction: Furosemide (FUR) remains the cornerstone agent to decongest patients with heart failure. Given the challenges associated with intravenous (IV) administration, an 80mg/10mL buffered ...
The pre-programmed device delivers 30mg of furosemide over the first hour followed by 12.5mg per hour for the subsequent 4 hours. The Food and Drug Administration (FDA) has approved Lasix ® ONYU ...
The U.S. Food and Drug Administration has approved Lasix ONYU, an at-home version of the common heart failure drug Lasix The device allows safe treatment for fluid buildup without hospital IV infusion ...
JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and ...
ZUG, Switzerland, Oct. 8, 2025 /PRNewswire/ -- SQ Innovation AG, a life-science company pioneering innovative solutions for the treatment of worsening heart failure, today announced the appointment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results